KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 6037 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Long-Term Survival Outcomes of Immune Checkpoint Inhibitor-based Combination Therapies in Favorable-Risk Metastatic Renal Cell Carcinoma: An Updated Pairwise and Network Meta-Analysis. PMID 42350220 · Clin Genitourin Cancer · 2026-Jun-03 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Safety of remibrutinib in chronic spontaneous urticaria: a pooled analysis of REMIX-1 and REMIX-2 trials. PMID 42242425 · J Allergy Clin Immunol Pract · 2026-Jun-03 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
JAAD Game Changers: A novel lotion formulation of 20% oxybutynin hydrochloride for the treatment of primary palmar hyperhidrosis: a randomized, placebo-controlled, double-blind, phase III study. PMID 42242363 · J Am Acad Dermatol · 2026-Jun-03 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Mesenchymal stromal cell infusions of umbilical cord-derived mesenchymal stromal cells in children with Recessive Dystrophic Epidermolysis Bullosa (MissionEB): a qualitative sub study of a randomised, double-blind, placebo controlled, crossover, phase 3 trial. PMID 42237200 · Orphanet J Rare Dis · 2026-Jun-03 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Clinical efficacy and safety of aflibercept biosimilars in neovascular age-related macular degeneration: a systematic review and meta-analysis of randomised controlled trials. PMID 42236129 · Br J Ophthalmol · 2026-Jun-03 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Daratumumab in Transplant-Ineligible or -Deferred Newly Diagnosed Multiple Myeloma: Minimal Residual Disease in CEPHEUS. PMID 42234958 · Blood Adv · 2026-Jun-03 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H B
影子组漏检补回 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Old and New Lines of Therapy Targeting Lipoprotein(a). PMID 42234287 · Curr Atheroscler Rep · 2026-Jun-03 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
STS101 nasal powder as a new treatment option for acute migraine with or without aura in adults. PMID 42217235 · Expert Rev Neurother · 2026-Jun-03 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Obexelimab for the Treatment of IgG4-Related Disease. PMID 42233621 · N Engl J Med · 2026-Jun-02 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-term effect of sweeteners and sweetness enhancers on gene expression markers of adipose tissue function, adipocyte morphology, and metabolic health: a SWEET substudy. PMID 42230988 · Int J Obes (Lond) · 2026-Jun-02 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Adjunctive Mechanical Ventilation or Intravenous Hypertonic Saline in Malawian Children with Cerebral Malaria and Highly Increased Brain Volume: A Randomized, Phase 3 Clinical Trial. PMID 42230477 · Neurocrit Care · 2026-Jun-02 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Determining the cutpoint of a continuous predictive biomarker via Bayesian sensitive subpopulation finding. PMID 42228058 · J Biopharm Stat · 2026-Jun-02 The record describes a Phase III randomized trial in advanced breast cancer with a time-to-event endpoint, but the publication is a methodological paper applying a new statistical method to trial data, not the original trial report. It does not explicitly state a drug intervention, and it is not a formal result report.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized Clinical Trial. PMID 42234428 · JAMA Netw Open · 2026-Jun-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer. PMID 42229584 · Ann Oncol · 2026-Jun-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial. PMID 42224659 · JAMA Oncol · 2026-Jun-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial. PMID 42224490 · JAMA · 2026-Jun-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Extension of the Phase 3 Trial of Somatrogon in Children with Growth Hormone Deficiency: 3 Years of Safety and Efficacy. PMID 42224388 · Horm Res Paediatr · 2026-Jun-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
THRIVE: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of Veligrotug for Active Thyroid Eye Disease. PMID 42223386 · Ophthalmology · 2026-Jun-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial. PMID 42223137 · J Clin Oncol · 2026-Jun-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in HER2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer. PMID 42223130 · J Clin Oncol · 2026-Jun-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Additivity, Not Synergy, Underlies the Efficacy of Current Combination Regimens in Urothelial Cancer. PMID 42219560 · Cancer Res Commun · 2026-Jun-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 2 Figure · 11 Panel · risk visible
Correction to: Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM). PMID 42096282 · Kidney360 · 2026-Jun-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Response to PCSK9 Inhibition Based on LDL Receptor Function in Familial Hypercholesterolemia: A Nonrandomized Clinical Trial. PMID 42054033 · JAMA Cardiol · 2026-Jun-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Recombinant ADAMTS13 in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis. PMID 41934124 · Blood Coagul Fibrinolysis · 2026-Jun-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Erratum to: Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. PMID 41746815 · Neuro Oncol · 2026-Jun-01 The record is a published erratum to a trial report. It does not contain the original trial results or primary/secondary efficacy endpoint data. While the title references a Phase III RCT, the erratum itself cannot be considered the original formal-result report of the trial.
H
仅历史库存 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Treatment Effect of Beta-Blocker Therapy After Acute Myocardial Infarction With Preserved or Mildly Reduced Ejection Fraction: A Systematic Review and Trial Sequential Analysis. PMID 42473525 · Cureus · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: CheckMate 9DW Japanese Subgroup Analysis. PMID 42338692 · Liver Cancer · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Optimal Use of Targeted Therapy and Immunotherapy in Early-Stage, Resectable Non-Small Cell Lung Cancer. PMID 42335416 · Am Soc Clin Oncol Educ Book · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Corrigendum to "Efficacy and safety of semaglutide injection in comparison with reference semaglutide for chronic weight management in Indian adults with obesity: A phase III randomized non-inferiority trial" [Metabol Open 30 (2026) 100460]. PMID 42327013 · Metabol Open · 2026-Jun 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effects of Quadriceps Strengthening Exercise with Blood Flow Restriction on Knee Angular Velocity, Strength, and Balance in Fencers. PMID 42318262 · J Sports Sci Med · 2026-Jun 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
IGLV3-21R110 and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLL. PMID 42306064 · Hemasphere · 2026-Jun 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 3 Figure · 11 Panel · risk unclear
Analysis of Viral Blips Through Week 192 of the DRIVE-FORWARD and DRIVE-AHEAD Phase 3 Studies of Doravirine-Based Regimens in Adults Living With Previously Untreated HIV-1. PMID 42281892 · Open Forum Infect Dis · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Oral Anticoagulation in Systemic Sclerosis-Related Pulmonary Arterial Hypertension-Results From the SPHInX Study. PMID 42266819 · Pulm Circ · 2026-Jun 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Hepatic Arterial Infusion Chemotherapy plus either Toripalimab or Sorafenib as First-line Therapy for Locally Advanced Hepatocellular Carcinoma: A Non-comparative, Randomized Phase 2 Trial. PMID 42266185 · MedComm (2020) · 2026-Jun 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 1 Figure · 2 Panel · risk visible
Zoliflodacin for uncomplicated gonorrhea: clinical evidence and implications beyond ceftriaxone plus azithromycin. PMID 42254149 · Ann Med Surg (Lond) · 2026-Jun 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of novel formulation of semaglutide injection: A multicentre, randomized, comparative, active controlled, phase 3 study in comparison with reference biologic in Indian patients with type 2 diabetes mellitus. PMID 42253408 · Metabol Open · 2026-Jun 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The Efficacy of Nicotinamide in Maintaining Mean Deviation in Glaucoma: A Systematic Review. PMID 42244899 · Cureus · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Clinical implications of skincare: lessons from placebo-controlled dermatology trials. PMID 42222690 · Skin Health Dis · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-experienced people with HIV-1: a systematic literature review and network meta-analysis. PMID 42206806 · J Comp Eff Res · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The use of memantine for prevention of Alzheimer's disease: Pilot feasibility study rationale and protocol. PMID 42179865 · Contemp Clin Trials Commun · 2026-Jun 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Therapeutic update on alopecia areata: a critical review of standard and emerging targeted therapies. PMID 42176145 · Inflammopharmacology · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Postmastectomy Radiotherapy With Immediate Implant Reconstruction: Treatment Fractionation, Implant Plane, and Clinical Outcomes. PMID 42173060 · Clin Breast Cancer · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Smoldering Multiple Myeloma: From Clinical to Immunogenomic Risk Stratification and Therapeutic Implications of Early Intervention. PMID 42172562 · Am Soc Clin Oncol Educ Book · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Severe Adverse Events in Neoadjuvant Therapy of Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Phase 3 Trials. PMID 42161782 · Clin Breast Cancer · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Regulatory approval of new oncology drugs, 2020-2024: A comparative analysis of FDA, EMA, and ANVISA. PMID 42142604 · J Cancer Policy · 2026-Jun The record is a comparative analysis of oncology drug approvals by regulatory agencies (FDA, EMA, ANVISA), not an original report of a randomized clinical trial with a time-to-event efficacy endpoint. It does not meet the criterion of being an original result report of a trial.
H S B
严格 v3 独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Efficacy and safety of adjuvant transarterial chemoembolization in high-risk HCC after curative hepatectomy: a phase III RCT protocol. PMID 42125606 · ILIVER · 2026-Jun 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
Efficacy, pharmacodynamics, pharmacokinetics, safety, and immunogenicity of Bmab 1000 vs reference denosumab: 78-wk results from a randomized, double-blind, multicenter, parallel-arm Phase 3 trial (DEVOTE) in women with postmenopausal osteoporosis. PMID 42110973 · JBMR Plus · 2026-Jun 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial. PMID 42086981 · Nat Med · 2026-Jun 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Cardiovascular outcomes of novel SGLT2 inhibitors in patients with type 2 diabetes: a network meta-analysis of bexagliflozin, ertugliflozin and sotagliflozin. PMID 42086086 · Diabetes Res Clin Pract · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Cost-effectiveness of frontline eltrombopag with immunosuppressive therapy for severe aplastic anemia. PMID 42077391 · Blood Red Cells Iron · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -